Quince Therapeutics (QNCX) Appoints Charles S. Ryan as President
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
September 6, 2023 7:00 AM EDTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the companys corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince.
Dirk Thye, M.D., Quinces... More
